Omnia Health is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Emerging treatments in amblyopia

Article-Emerging treatments in amblyopia

amblyopia.jpg

Recent research on amblyopia (commonly known as lazy eye) reviewed the impact of the disorder on the brain. Led by Bas Rokers, Associate Professor of Psychology, NYU Abu Dhabi, the paper has been published in the Journal of Binocular Vision and Ocular Motility.

Amblyopia is the most common developmental visual disorder, affecting about four per cent of children globally. Treatment using traditional methods (patching) is only successful in about half of cases. The paper lays the groundwork for evaluating the impact of new treatment methods including virtual reality-based video games, that force the two eyes to work together, as well as neuropharmacological interventions that can induce neural plasticity past the critical period. In an interview with Omnia Health Insights, Rokers explains more about the findings.

What is the impact of amblyopia on the brain?

Amblyopia is characterised by abnormal visual input to the brain during childhood, which leads to an abnormal developmental trajectory. While it is clear that this affects both the structure and function of the brain’s visual system, the exact nature and extent of the changes are an area of active research. Whether the effects of amblyopia can be reversed is an especially important area of study.

How can it be treated?

Standard treatment is through occlusion, i.e., patching of the dominant eye. Current research is exploring the potential additional benefits of virtual and augmented reality therapy as well as pharmacological intervention.

An important question is whether all amblyopia is the same – and can thus be treated with the same methods – or are there specific subtypes? Answering this question requires analysis of large datasets collected across multiple time points from a variety of patients. Should we find different subtypes of amblyopia with separate neural causes, this would suggest different, personalised, treatment for different patient populations.

We are currently exploring studies on the neural basis of amblyopia and potential new treatments in the UAE in collaboration with Cleveland Clinic.

How can neuropharmacological interventions help?

It is commonly held that intervention after about 7 or 8 years of age is ineffective, due to reduced neural plasticity in the visual system after that time. Neuropharmacological intervention might help ‘release the brakes’ on neural plasticity.

Bas Rokers-min.jpg

Bas Rokers

Breakthrough in non-invasive medical technology

Article-Breakthrough in non-invasive medical technology

brain.jpg

Chronic conditions (both neurological and systemic) often originate from dysfunctions of the brainstem or hypothalamus. For example, downregulation of the hypothalamus can cause insulin resistance and therefore lead to type two diabetes and obesity. Similarly, dysfunction in the circadian regulation centre of the hypothalamus can lead to insomnia.

Whilst medications can influence neurons of the hypothalamus, they will also lead to cross-activation of similar receptors in other areas leading to significant side effects (such as increased mental health issues or cardiovascular disease). By stimulating the required neurons directly using electricity, the patient has a much greater outcome with significantly reduced side effects.

This where Neurovalens comes in. The Northern Ireland-based company makes non-invasive technology that can stimulate the deep parts of the brain and brainstem.

The company’s CEO, Dr Jason McKeown, told Omnia Health Insights: “Our technology, which is worn like a headband, is typically used for 30 minutes each day and is user-controlled via connection to their mobile phone. Our main focus is our insomnia and anxiety treatments (US FDA approval is pending) and our longer-term work is in the area of metabolic disease (Currently at Phase 3 trials). Ultimately, we would like to offer a drug-free treatment for four diseases – insomnia, anxiety, type 2 diabetes, and obesity.”

McKeown highlights that the company’s good relationship with the U.S. FDA allowed it to have early meetings designed to ensure clinical trial participants were able to complete the trials safely and effectively, despite the challenges posed by COVID-19. “Most of this was via our remote-trial plan, which we were able to action with the FDA directly,” he added.

Separately, outside of the U.S. market, Neurovalens have noticed a significant increase in the sales of its CE certified Sleep & Stress technology. These devices can be issued without a prescription and non-U.S. customers can have their device sent directly from Neurovalens via online orders.

At the upcoming ‘Northern Ireland: Providing innovative solutions to the world’s healthcare challenges’ webinar, Neurovalens will shed light on its two expected medical device approvals (insomnia and anxiety treatment) in the coming months.

“We are hoping to subsequently register these products in several Middle East regions,” he said. “At this stage, we are keen to highlight this novel technology and discuss with distributors and healthcare networks about integration into their treatment offering.”

Jason.jpg

Dr Jason McKeown

McKeown concluded: “Although Neurovalens’ immediate focus is on the neurological treatments; we are aiming to have approval for diabetes and obesity technology by early 2021. Therefore, we would also be happy to speak with anyone who has a more specific focus of type 2 diabetes or metabolic disease.

Join the webinar: Northern Ireland: Providing innovative solutions to the world’s healthcare challenges
Tuesday 9th February – 3PM GST

You can hear more from Neurovalens at this webinar hosted by Invest Northern Ireland, the economic development agency for Northern Ireland, UK. With expertise across a range of specialisms, including respiratory products, diagnostics, medical devices, e-health and medtech, companies from Northern Ireland are enabling treatments that transform lives across the globe.

Register for free >>